Addiction News and Research

RSS

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

South Dakota State University researchers have demonstrated for the first time that a plant-derived compound used to treat nicotine addiction also has significant effects against alcohol addiction.

21 Oct 2010

Study on health effects of alcohol consumption with HIV

Living with HIV is difficult under the best of circumstances, but for people carrying the virus, alcohol consumption can become particularly perilous in intricate ways that are only beginning to be understood. At the Brown Alcohol Research Center on HIV (ARCH) funded by a new $7.5-million, five-year grant from the National Institutes of Health, Brown University scientists will study the health effects of drinking with HIV and provide doctors and patients with the latest guidance their results suggest.

21 Oct 2010

Employers not dropping coverage as Mental Health Parity law is enacted

American Medical News: The Mental Health Parity and Addiction Equity Act hasn't made employers drop coverage as some feared it might. The full effects won't be felt until early 2011 as health plans begin their new enrollment years, but "[e]arly indications ... are that relatively few employers are dropping mental health coverage in response to the law's mandate, a concern of some of the bill's opponents."

21 Oct 2010

Celebrity health messages play an important role in society: Study

Celebrity journalism is often considered to be without merit, discounted due to its sensational details and lack of news value. MU researchers now say that celebrity journalism may be an underappreciated way to communicate health messages. In a recent award-winning paper, Amanda Hinnant, assistant professor of magazine journalism in the University of Missouri School of Journalism, found some readers of celebrity health stories report that the stories have an impact on their own behavior and how they discuss health issues.

19 Oct 2010

Few legitimate opioid users are getting information to keep medications safe

For some people with ongoing or chronic pain, opioids (medications such as oxycodone or hydrocodone) can make the difference between disability and the ability to function at near-normal levels. For those with acute pain, such as pain after surgery or injury, sound pain management with opioids can speed healing and recovery.

19 Oct 2010

Researchers discover how cocaine corrupts brains' reward center

Mount Sinai researchers have discovered how cocaine corrupts the brain and becomes addictive. These findings-the first to connect activation of specific neurons to alterations in cocaine reward-were published in Science on October 15. The results may help researchers in developing new ways of treating those addicted to the drug.

19 Oct 2010

Dopamine behind mens susceptibility to alcoholism

Alcohol is one of the most commonly abused substances, and men are up to twice as likely to develop alcoholism as women. Until now, the underlying biology contributing to this difference in vulnerability has remained unclear.

19 Oct 2010

TV alcohol advertising ‘watershed’ called for in the UK

Protestors in Britain have called for a ‘watershed’ for alcohol advertising on TV amid claims that millions of children watched the ads during live World Cup games. Alcohol Concern UK says that children as young as four watched alcohol ads from brands such as Stella Artois, Magners, Fosters, Carling and WKD during the World Cup.

18 Oct 2010

Omeros receives additional NIDA grant for clinical studies in Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute.

14 Oct 2010

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

The U.S. Food and Drug Administration's approval of Alkermes' opioid dependence medication (VIVITROL) for the prevention of relapse to opioid dependence following opioid detoxification is positive news for families of young adults and all those who are struggling to overcome opioid addiction. Addiction, a disease of the human brain, is a chronic illness while opioid dependence is frequently characterized by relapse.

13 Oct 2010

JAMA publishes Probuphine Phase 3 clinical trial data

Titan Pharmaceuticals, Inc. today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA).

13 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

FDA approves Vivitrol for treatment of opioid-dependent patients

The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

13 Oct 2010

Mobile outreach program by sex workers provides key link to health, support services

A mobile outreach program staffed by current and former sex workers is associated with increased entry to detoxification and residential drug treatment among women in street-based sex work, according to an evaluation led by the BC Centre for Excellence in HIV/AIDS (BC-CfE) and the University of British Columbia (UBC).

12 Oct 2010

CMA to apply intervener status in Insite case

The Canadian Medical Association (CMA) Board of Directors has decided that the CMA will apply for intervener status before the Supreme Court of Canada in its pending appeal of a case involving Insite, the supervised injection facility in Vancouver, British Columbia.

8 Oct 2010

Semi-synthetic opioid may improve withdrawal symptoms in infants

Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.

7 Oct 2010

Health overhaul implementation updates: States fret, Sebelius hits The Hill

In a congressional appearance Monday, Health and Human Services Secretary Kathleen Sebelius asked lawmakers to move beyond politics and focus on successfully reforming American health care.

6 Oct 2010

Centre for Addiction and Mental Health selected as field trial sites for DSM-5 criteria

Toronto's Centre for Addiction and Mental Health (CAMH) has been selected as one of seven adult field trial sites in North America and the only site in Canada to test proposed diagnostic criteria for the American Psychiatric Association's (APA) fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM).

6 Oct 2010

Researchers to conduct trial to improve drug abstinence, relapse rates

A $15.7 million award from the National Institute on Drug Abuse (NIDA) is allowing researchers to see whether consistent exercise will help people abstain from stimulant abuse.

6 Oct 2010

CDC grant to support community-based public health project in RI and CT

A $250,000 grant from the Centers for Disease Control and Prevention (CDC) will support a Rhode Island Hospital research study aimed at reducing the state's leading cause of accidental death among adults. Researchers will explore the use and effectiveness of statewide prescription monitoring programs (PMP) in reducing the number of accidental overdose deaths involving prescription opioids like OxyContin and Vicodin in both Rhode Island and Connecticut.

6 Oct 2010